Rossari Biotech Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹698 Cr +19.1% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
RB

Rossari Biotech Ltd

Q1 FY27Chemicals & Petrochemicals

Rossari Biotech Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Revenue
₹697Cr
+28.1% YoY
+1.8% QoQ
Net profit
₹35Cr
+2.9% YoY
−23.9% QoQ
Margin
12%
0 pp YoY
+1 pp QoQ

What the Q1 FY27 call signalled

2 of 3 strong

RevenueModerate growth
MarginMargins up
CapexCapex planned
Price₹442
Market cap₹2.4K Cr
P/E16.1

The short version

FY27 revenue growth guidance is around 15%, despite Q1 showing a strong 28% growth (Page 7, 13). Rossari targets over 15% top-line growth annually, as reiterated for FY27 despite current global uncertainties.

From Rossari Biotech Ltd's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.

Revenue & Sales Performance

Moderate growth
  • FY27 revenue growth guidance is around 15%, despite Q1 showing a strong 28% growth (Page 7, 13).
  • Growth driven by ramp-up in utilization of new capacity and new products from recent expansions (Page 7).
  • Volume growth in Q1 was about 10%, with the remainder of top-line growth from price increases (Page 12).
  • Increased EO capacity expected by end of FY27 to drive healthy growth in FY27 and FY28 (Pages 12, 13).
  • New product introductions like vitamin premixes, enzymes, esters, and pharma segment to support volume expansion (Pages 11, 12).

2 more points from Rossari Biotech Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Rossari Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Current CAPEX in India has slowed down; only calibrated spending on new CAPEX is planned, focusing on new products/molecules such as pharma and aroma chemicals.
  • No large CAPEX planned for this year; focus is on utilizing existing capacities efficiently.
  • Early-stage operational and exploratory expenses have begun for the Saudi Arabia (KSA) greenfield project, despite the West Asia geopolitical situation.
  • The KSA project remains a key strategic initiative, with active engagement with partners, suppliers, consultants, and the Saudi ministry; plans include setting up downstream EO and non-EO products.
  • Expected gestation for KSA production start is around 1.5 years from investment announcement.

2 more points from Rossari Biotech Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Rossari Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Rossari Biotech Ltd said on order book & pipeline — free account, 30 seconds.

Rossari Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Rossari Biotech Ltd Q1 FY27 results — key figures

Rossari Biotech Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue697544+28.1%685+1.8%
Operating profit (EBITDA)8168+19.1%77+5.2%
Operating margin12%12%0 pp11%+1 pp
Profit before tax4846+4.3%64-25%
Net profit (PAT)3534+2.9%46-23.9%
EPS (₹)6.346.07+4.4%8.30-23.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹698 Cr, net profit ₹39 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Alufluoride (Q1 FY27)

    Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr

  • POCL Enterprises (Q1 FY27)

    466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto

  • Devson Catalyst (Q1 FY27)

    FY 2023-24: ₹5,577.59 Lakhs . Key investor presentation takeaways from Devson Catalyst Ltd's Q1 FY27 investor presentation — and how it ranks against sector pee

  • Ambani Orgochem (Q1 FY27)

    Financial highlights show Total Income in ₹ Lakhs: . Key investor presentation takeaways from Ambani Orgochem's Q1 FY27 investor presentation — and how it ranks

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Rossari Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Rossari Biotech Ltd Q1 FY27 results?

FY27 revenue growth guidance is around 15%, despite Q1 showing a strong 28% growth (Page 7, 13). Rossari targets over 15% top-line growth annually, as reiterated for FY27 despite current global uncertainties.

What is Rossari Biotech Ltd share price analysis?

Rossari Biotech Ltd currently shows a below-average growth signal. The stock trades at a P/E of 16.1 with a market cap of ₹2,426 Cr. Investors should review the full earnings analysis for detailed insights.

Is Rossari Biotech Ltd planning capital expenditure?

Current CAPEX in India has slowed down; only calibrated spending on new CAPEX is planned, focusing on new products/molecules such as pharma and aroma chemicals.

Keep Rossari Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.